Welcome to our dedicated page for Identa Rvice news (Ticker: IDTA), a resource for investors and traders seeking the latest updates and insights on Identa Rvice stock.
IDenta Corp (IDTA) is described in its public announcements as a worldwide or global leader in the development and supply of Field Detection and Home Diagnostic Testing Kits for narcotics, explosives and unique forensic products in the homeland security and consumer markets. Its news flow frequently combines financial updates with information about product focus, market expansion and operational efficiency.
On this page, readers can follow IDenta Corp news that covers quarterly and annual financial statements, commentary from management, and descriptions of how factors such as production optimization, marketing efforts and distributor expansion have influenced reported revenues, profits and cash levels. The company’s releases often highlight growth in sales, improvements in profitability and changes in cash and cash equivalents over time.
IDenta Corp’s news also provides insight into its product themes, including field detection kits and home diagnostic testing kits for drugs and explosives, as well as products designed to identify fentanyl and its derivatives. The company has described these fentanyl detection devices as quick, on-the-spot testing tools that are useful for law enforcement agencies, border control and workplace drug testing.
In addition, IDenta Corp issues news about shareholder meetings and corporate matters, such as proposed changes in company structure subject to board and shareholder approval. Investors and observers can use this news feed to review how the company presents its operational progress, market activities, and financial performance over multiple reporting periods.
IDenta Corp. (OTCQB: IDTA), a leader in developing field detection and home diagnostic testing kits, reported its 2022 third quarter financial results on November 15, 2022. Key highlights include a 31% increase in gross profit to $287,451 and a significant turnaround in operating profit to $19,870 from a loss of $12,177 the previous year. Net profit rose to $19,419 from a loss of $45,792. However, cash and cash equivalents fell to $324,475 from $347,151 year-over-year. The CEO emphasized the company's strong recovery and ongoing partnerships amid a challenging economic environment.
IDenta Corp. (OTCQB: IDTA) has introduced a new test kit to detect Fentanyl in Cocaine and Crack, responding to the urgent need for safety amid rising drug contamination. CEO Amichai Glattstein emphasized the kit's potential life-saving capabilities, highlighting that Fentanyl is often undetectable by sight or taste. Available for purchase online under the brand Touch&Know, the kit offers quick results at an affordable price. IDenta is recognized for its leading role in developing diagnostic kits for drugs and explosives.
IDenta Corp. (OTCQB: IDTA) will hold its 2022 Annual Shareholders' meeting on June 26, 2022, at 7:00 PM (GMT +3) in Jerusalem, Israel. The company specializes in developing Field Detection and Home Diagnostic Testing Kits for Narcotics, Explosives, and Forensic Products targeting Homeland Security and Consumer Markets. CEO Amichai Glattstein expressed enthusiasm for the upcoming meeting, looking forward to engaging with shareholders. The company is known for its innovative products, which adhere to the stringent standards of law enforcement and security agencies.
IDenta Corp. (OTCQB: IDTA) announced a promotional campaign for its Touch&Know drug and fentanyl detection kits on American Airlines flights, reaching approximately 80,000 flights in May 2022. The CEO emphasized the importance of accessibility to quality products that can save lives. The Touch&Know kits are available for purchase on the company’s website and Amazon throughout the U.S. IDenta Corp. is recognized as a leader in developing testing kits for narcotics and explosives in the homeland security and consumer markets.
IDenta Corp. (OTCQB: IDTA), a leader in developing drug and explosive detection kits, has secured a contract to supply drug test kits to Italy's security forces. The contract follows extensive product testing, demonstrating IDenta's superior technology and pricing compared to competitors. CEO Amichai Glattstein emphasized this achievement as a significant milestone for international expansion, noting Italy's vital role in drug detection efforts. IDenta aims to enhance operations in more countries, providing innovative solutions for a safer future.
IDenta Corp. (OTCQB: IDTA) has been awarded a significant contract to supply 220,000 drug test kits to Italy's security forces after extensive testing proved their products' superiority. CEO Amichai Glattstein emphasized the importance of this achievement and the company's ongoing expansion into international markets. IDenta continues to innovate and provide advanced solutions in the drug detection sector, enhancing its competitive edge in technology and pricing.
IDenta Corp. (OTCQB: IDTA) reported its 2021 annual financial results, showing profitability amidst global challenges from the COVID pandemic. Revenue decreased by 4% to $1,392,136, while gross profit rose 12% to $1,065,965. Operating profit fell 39% to $214,151 due to new operations in the US and increased labor costs. Net profit also declined by 80% to $69,183, impacted by currency exchange rates and unforeseen tax payments. Cash and equivalents decreased to $347,151. Despite challenges, the company seeks new sales avenues and market entry.
IDenta Corp. (OTC-QB: IDTA) announces the opening of a new front office in the Washington D.C. area, marking a significant step in its operations. The office will be led by CEO Amichai Glattstein, who relocated from Israel to enhance business ties with U.S. government offices and security companies. IDenta evaluates the U.S. market potential for its detection kits at tens of millions of dollars annually, indicating strong growth prospects. This move aims to penetrate the U.S. market effectively, thereby benefiting global expansion.
IDenta Corp. (OTCQB: IDTA) reported a decline in its third quarter 2021 financial results, with revenues of $335,121, down from $496,108 in Q3 2020. Gross profit decreased to $219,286 versus $392,596 last year. Operating loss stood at $(12,177), contrasting with an operating profit of $283,232 in Q3 2020. The net loss was $(45,792), compared to net profit of $282,232 in the same period last year. Factors impacting results included project freezes due to COVID-19, new tax payments, and unfavorable exchange rates. However, the launch of online sales in the US market is expected to support future revenue growth.
IDenta Corp. (OTCQB: IDTA) has launched a unique patent kit on Amazon capable of identifying 30 types of illicit drugs with a single test, marking it as the first of its kind globally. The CEO, Amichai Glattstein, highlighted the rarity of launching a patented product on Amazon, emphasizing the significant market potential in Home Diagnostics and Drug Detection Solutions. This innovative product aims to position IDenta as a major player in the online retail market for drug detection.